You can buy or sell NERV and other stocks, options, ETFs, and crypto commission-free!
Minerva Neurosciences, Inc Common Stock, also called Minerva Neurosciences, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. Read More The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 13
Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug
Shares of the microcap biotech Minerva Neurosciences Inc (NASDAQ: NERV) were pulling back to their lowest level in a year Monday following the release of a clinical trial readout.
Yahoo FinanceMay 7
Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for Minerva Neurosciences, Inc. (NASDAQ:NERV) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to their present value. I will use the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward. We genera...
Seeking AlphaMay 6
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2019 Results - Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q1 2019 Results Conference Call May 6, 2019 8:30 AM ET Company Participants William Boni - Vice President of Investor Relations and Corporate Communications Remy Luthringer - Executive Chairman and Chief Executive Officer Rick Russell - President Geoff Race - Executive Vice President, Chief Financial Officer and Chief Business Officer Conference Call Participants Roy Buchanan - JMP Securities Joel Beatty - Citigroup Operator Welcome to the Minerva Neurosci...
Expected Aug 1, Pre-Market